Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, Tyler J., Wei, Shuang, Dong, Haidong, Alvarez, Xavier, Cheng, Pui, Mottram, Peter, Krzysiek, Roman, Knutson, Keith L. +14 more·2003·Nature Medicine
DOI 10.1038/nm863

Cited by (1,000)

Items 401–500 of 1,000

  1. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
    Shingo Inaguma, Zengfeng Wang, Jerzy P. Lasota, Maarit Sarlomo‐Rikala, Peter A. McCue, Hiroshi Ikeda, Markku Miettinen · 2016 · The American Journal of Surgical Pathology
  2. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
    Maarten Versteven, Johan M.J. Van den Bergh, Elly Marcq, Evelien Smits, Viggo F. Van Tendeloo, Willemijn A. Hobo, Eva Lion · 2018 · Frontiers in Immunology
  3. Immunotherapy of cancers comes of age
    Hila Yousefi, Jianda D. Yuan, Mahsa Keshavarz‐Fathi, Joseph F. Murphy, Nima Rezaei · 2017 · Expert Review of Clinical Immunology
  4. Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor
    Ce Wang, Xue F. Huang, Yingjuan Wu, Jingbo Wang, Furong Li, Guoqing Guo · 2020 · International Journal of Biological Sciences
  5. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
    Yan Ge, Xi Hong, Songguang Ju, Xueguang Zhang · 2013 · Cancer Letters
  6. Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin
    Lana Elias Kandalaft, Gregory T. Motz, Johanna I. Busch, George Coukos · 2010 · Current topics in microbiology and immunology
  7. The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
    Nona Janikashvili, Bernard Bonnotte, Emmanuel Katsanis, Nicolas Larmonier · 2011 · Clinical and Developmental Immunology
  8. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
    Saito, Hiroaki, Kuroda, Hirohiko, Matsunaga, Tomoyuki, Osaki, Tomohiro, Ikeguchi, Masahide · 2013 · Journal of Surgical Oncology
  9. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
    Tokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, Akihiko Kawahara, Ko Ideguchi, Daisuke Sugiyama, Fumio Kinoshita, Jun Akiba, Eiji Kashiwagi, Ario Takeuchi et al. · 2019 · Clinical Cancer Research
  10. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
    Yang Wang, Ning Zhao, Zhanbo Wu, Na Pan, Xuejie Shen, Ting Liu, Feng Wei, Jian You, Wengui Xu, Xiubao Ren · 2019 · European Journal of Nuclear Medicine and Molecular Imaging
  11. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
    Anna Śledzińska, Laurie Menger, Katharina F. Bergerhoff, Karl S. Peggs, Sergio A. Quezada · 2015 · Molecular Oncology
  12. Spatial Regulation of T‑Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets
    Trixy Fang, Jonatan Alvelid, Joel Spratt, Elena Ambrosetti, Ilaria Testa, Ana I. Teixeira · 2021 · ACS Nano
  13. The Anergic State in Sarcoidosis Is Associated with Diminished Dendritic Cell Function
    Sneha Mathew, Kristy L. Bauer, Arne Fischoeder, Nina Bhardwaj, Stephen John Oliver · 2008 · The Journal of Immunology
  14. Interleukin‐17‐educated monocytes suppress cytotoxic T‐cell function through B7‐H1 in hepatocellular carcinoma patients
    Qiyi Zhao, Christos Xiao, Yan Wu, Yi Wei, Lingyan Zhu, Jia Zhou, Dong‐Ming Kuang · 2011 · European Journal of Immunology
  15. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances
    Jonathan L. Messerschmidt, George C. Prendergast, Gerald L. Messerschmidt · 2016 · The Oncologist
  16. The complex role of B7 molecules in tumor immunology
    Barbara Seliger, Francesco Maria Marincola, Soldano Ferrone, Hinrich Abken · 2008 · Trends in Molecular Medicine
  17. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines
    Lingyun Yang, Feng Huang, Jiandong Mei, Xun Wang, Qiuyang Zhang, Hongjing Wang, Mingrong Xi, Zongbing You · 2016 · International Journal of Gynecological Cancer
  18. LIN28/ let-7 /PD-L1 Pathway as a Target for Cancer Immunotherapy
    Yanlian Chen, Chen Xie, Xiaohui Zheng, Xin Nie, Zining Wang, Haiying Liu, Yong Bo Zhao · 2019 · Cancer Immunology Research
  19. Anti–PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates
    Zilong Wang, Changyu Jiang, Qianru He, Megumi Matsuda, Qingjian Han, Kaiyuan Wang, Sangsu Bang, Huiping Ding, Mei‐Chuan Ko, Ru‐Rong Ji · 2020 · Science Translational Medicine
  20. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage
    Colette Dezutter‐Dambuyant, Isabelle Durand, Laurent Alberti, Nathalie Bendriss‐Vermare, Jenny Valladeau‐Guilemond, Adeline Duc, Audrey Magron, Anne‐Pierre Morel, Vanja Sisirak, Céline Rodriguez et al. · 2015 · OncoImmunology
  21. Cutting Edge: IFN-γ Enables APC to Promote Memory Th17 and Abate Th1 Cell Development
    Ilona Kryczek, Shuang Wei, Wenrong Gong, Xiaogong Shu, Wojciech Szeliga, Linhua Vatan, Lieping Chen, Guobin Wang, Weiping Zou · 2008 · The Journal of Immunology
  22. Notch2 Signaling Is Required for Potent Antitumor Immunity In Vivo
    Koji Sugimoto, Yoichi Maekawa, Akiko Kitamura, Jun Nishida, Akemi Koyanagi, Hideo Yagita∥, Hidefumi Kojima, Shigeru Chiba, Mitsuo Shimada, Koji Yasutomo · 2010 · The Journal of Immunology
  23. Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
    Anke Kretz-Rommel, Fenghua Qin, Naveen K. Dakappagari, Roxanne Cofiell, Susan J. Faas, Katherine S. Bowdish · 2008 · The Journal of Immunology
  24. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
    Kelly Kersten, Camilla Salvagno, Karin E. de Visser · 2015 · Frontiers in Immunology
  25. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
    Nina Prokoph, Hugo Larose, Megan S. Lim, G.A. Amos Burke, Suzanne Dawn Turner · 2018 · Cancers
  26. Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
    Nadia Bannoud, Tomás Dalotto‐Moreno, Lucía Kindgard, Pablo A. García, Ada Gabriela Blidner, Karina Valeria Mariño, Gabriel A. Rabinovich, Diego Omar Croci · 2021 · Frontiers in Immunology
  27. Tumor stress, cell death and the ensuing immune response
    Evelyn Ullrich, Mathieu Bonmort, Grégoire Mignot, Guido Kroemer, Laurence Zitvogel · 2007 · Cell Death and Differentiation
  28. Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS–STING Signaling in Triple-Negative Breast Cancer
    Yang Hu, Baraa K. Manasrah, Stephanie M. McGregor, Robert F. Lera, Roshan X. Norman, John B. Tucker, Christina M. Scribano, Rachel E. Yan, Mouhita Humayun, Kari Braun Wisinski et al. · 2021 · Molecular Cancer Therapeutics
  29. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
    Young–Jin Choi, Su Hyun Seok, Hong Yeol Yoon, Ju Hee Ryu, Ick Chan Kwon · 2024 · Advanced Drug Delivery Reviews
  30. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients
    Alan N. Gordon, Birgit C. Schultes, Holly H. Gallion, Robert P. Edwards, Theresa L. Whiteside, Jennifer Marie Cermak, Christopher F. Nicodemus · 2004 · Gynecologic Oncology
  31. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy
    Zhi‐Chun Ding, Lei Huang, Bruce R. Blazar, Hideo Yagita∥, Andrew L. Mellor, David H. Munn, Gang Zhou · 2012 · Blood
  32. Basics of PD-1 in self-tolerance, infection, and cancer immunity
    Shunsuke Chikuma · 2016 · International Journal of Clinical Oncology
  33. IL-27 renders DC immunosuppressive by induction of B7-H1
    Svetlana Karakhanova, Tanja Bedke, Alexander Enk, Karsten Mahnke · 2011 · Journal of Leukocyte Biology
  34. PD-L1 and tumor-associated macrophages in de novo DLBCL
    Ronald McCord, Christopher R. Bolen, Hartmut Koeppen, Edward Ernest Kadel, Mikkel Z. Oestergaard, Tina G. Nielsen, Laurie Helen Sehn, Jeffrey Michael Venstrom · 2019 · Blood Advances
  35. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions
    Soumaya Allouch, Ahmed M Malki, Asma Allouch, Ishita Gupta, Semir Vranić, Ala‐Eddin Al Moustafa · 2020 · Frontiers in Oncology
  36. HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
    Shamaila Munir Ahmad, Gitte Holmen Olofsson, Özcan Met, Marco Donia, Thomas Mørch Frøsig, Stine Kiær Larsen, Tobias Wirenfeldt Klausen, Inge Marie Svane, Mads Hald Andersen · 2013 · Cancer Research
  37. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
    Tom Ehlen, Paul J Hoskins, D. MILLER, Theresa L. Whiteside, Christopher F. Nicodemus, Birgit C. Schultes, Ken Swenerton · 2005 · International Journal of Gynecological Cancer
  38. Tumor Induced Inactivation of Natural Killer Cell Cytotoxic Function; Implication in Growth, Expansion and Differentiation of Cancer Stem Cells
    Anahid Jewett, Han-Ching Tseng · 2011 · Journal of Cancer
  39. Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations
    Elio Schouppe, Patrick DE BAETSELIER, Jo A. Van Ginderachter, Adélaïda Sarukhan · 2012 · OncoImmunology
  40. Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1–Mediated Immune Suppression
    Samuel T. Haile, Sonia P. Dalal, Virginia K. Clements, Koji Tamada, Suzanne Ostrand‐Rosenberg · 2013 · The Journal of Immunology
  41. Immune checkpoint therapy for pancreatic cancer
    Henrik Johansson, Roland E. Andersson, Monika Posaric Bauden, Sarah Hammes, Stefan Holdenrieder, Daniel Ansari · 2016 · World Journal of Gastroenterology
  42. Autocrine and Paracrine Chemokine Receptor 7 Activation in Head and Neck Cancer: Implications for Therapy
    Jie Wang, Raja R. Seethala, Qing Hua Zhang, W. Gooding, Carter Van Waes, Hitoshi Hasegawa, Robert Louis Ferris · 2008 · JNCI Journal of the National Cancer Institute
  43. Immune Cell Population in Ovarian Tumor Microenvironment
    Dong-Li Cai, Liping Jin · 2017 · Journal of Cancer
  44. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
    Mandy van Gulijk, Floris F. Dammeijer, Joachim G.J.V. Aerts, Heleen H. Vroman · 2018 · Frontiers in Immunology
  45. Targeting regulatory T cells
    Christine Ménétrier‐Caux, Tyler Jay Curiel, Julien Faget, Manuarii Manuel, Christophe Caux, Weiping Zou · 2012 · Targeted Oncology
  46. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD‐1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma
    Hui Geng, Guimei Zhang, Xiao Han, Ye Yuan, Dong Li, Hui Zhang, Hui Qiu, Yufei He, Zuo‐Hua Feng · 2006 · International Journal of Cancer
  47. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
    Shu‐Jin Li, J.Y. Chen, Zhi‐Jun Sun · 2021 · 癌症：英文版
  48. Immunosuppressive effects of vascular endothelial growth factor (Review)
    Doménico Ribatti · 2022 · Oncology Letters
  49. Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer
    David C. Binder, Boris Engels, Ainhoa Arina, Ping Yü, James M. Slauch, Yang‐Xin Fu, Theodore G Karrison, Byron Burnette, Christian Idel, Ming Dan Zhao et al. · 2013 · Cancer Immunology Research
  50. Enhancement of Dendritic Cells as Vaccines for Cancer
    Meghan E. Turnis, Cliona M. Rooney · 2010 · Immunotherapy
  51. State of the art in anti-cancer mAbs
    Sebastián Matias Chiavenna, Juan Pablo Jaworski, A. Vendrell · 2017 · Journal of Biomedical Science
  52. CD277 is a Negative Co-stimulatory Molecule Universally Expressed by Ovarian Cancer Microenvironmental Cells
    Juan R. Cubillos‐Ruiz, Diana G. Martinez, Uciane K. Scarlett, Melanie R. Rutkowski, Yolanda C. Nesbeth, Ana L. Camposeco-Jacobs, Jose Ramon Conejo-Garcia · 2010 · Oncotarget
  53. Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
    Robert Donald Harvey · 2014 · Clinical Pharmacology & Therapeutics
  54. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
    Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, Doriana Fruci, Federica Gemignani · 2020 · Seminars in Cancer Biology
  55. Immunoregulatory role of B7-H1 in chronicity of inflammatory responses.
    Haidong Dong, Xian‐Ming Chen · 2006 · PubMed
  56. Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
    Liu, Jiaxing, Peng, Xueqiang, Yang, Shuo, Li, Xinyu, Huang, Mingyao, Wei, Shibo, Zhang, Sheng, He, Guangpeng, Zheng, Hongyu, Fan, Qing et al. · 2022 · Cell Communication and Signaling
  57. Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy
    Yufei He, Xiaohong Wang, Guimei Zhang, Hongtao Chen, Hui Zhang, Zuo‐Hua Feng · 2005 · Cancer Immunology Immunotherapy
  58. The Immune System in the Pathogenesis of Ovarian Cancer
    Bridget Charbonneau, Ellen L. Goode, Kimberly R. Kalli, Keith L. Knutson, Melissa S. DeRycke · 2013 · Critical Reviews in Immunology
  59. IL-6 and Leukemia-Inhibitory Factor are Involved in the Generation of Tumor-Associated Macrophage: Regulation by IFN-γ
    Pascale Jeannin, Dorothée Duluc, Yves Delneste · 2011 · Immunotherapy
  60. Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
    Melita B. Irving, Romain Vuillefroy de Silly, Kirsten B. J. Scholten, Nahzli Dilek, George Coukos · 2017 · Frontiers in Immunology
  61. Emerging Mechanisms of Immunosuppression in Oral Cancers
    Anahid Jewett, Christian S. Head, Nicholas A. Cacalano · 2006 · Journal of Dental Research
  62. T lymphocyte co-signaling pathways of the B7-CD28 family.
    Shengdian Wang, Lieping Chen · 2004 · PubMed
  63. Suppressive Influences in the Immune Response to Cancer
    Vincenzo Bronte, Simone Mocellin M. D · 2008 · Journal of Immunotherapy
  64. Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine
    W. Scott Webster, Robert Houston Thompson, Kimberley J Harris, Xavier Frigola, Susan M. Kuntz, Brant Allen Inman, Haidong Dong · 2007 · The Journal of Immunology
  65. Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
    Angela Vasaturo, Stefania Di Blasio, Deborah G. A. Peeters, Coco C. H. de Koning, I. Jolanda M. de Vries, Carl Gustav Figdor, Stanleyson V. Hato · 2013 · Frontiers in Immunology
  66. Programmed cell death-1 inhibition in lymphoma
    Eliza Anne Hawkes, Andrew Grigg, Geoff Chong · 2015 · The Lancet Oncology
  67. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
    Wang, Yiming, Ma, Rena, Liu, Fang, Lee, Seul A., Zhang, Li · 2018 · Frontiers in Immunology
  68. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy
    Zhu, Shan, Yang, Ning, Wu, Jing, Wang, Xue, Wang, Wan, Liu, Yong-Jun, Chen, Jingtao · 2020 · Pharmacological Research
  69. B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence
    Jonathan C. Routh, Richard Ashley, Thomas J. Sebo, Christine Marie Lohse, Douglas A. Husmann, Stephen A. Kramer, Eugene D. Kwon · 2008 · The Journal of Urology
  70. Immune checkpoint inhibitors in ovarian cancer: where do we stand?
    Alexandra F. Leary, David S.P. Tan, Jonathan Andrew Ledermann · 2021 · Therapeutic Advances in Medical Oncology
  71. Tumor-Mediated Neutrophil Polarization and Therapeutic Implications
    Sofia Raftopoulou, Paulina Valadez-Cosmes, Zala Nikita Mihalič, Rudolf Schicho, Julia Kargl · 2022 · International Journal of Molecular Sciences
  72. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype
    Zhi‐Chun Ding, Bruce R. Blazar, Andrew L. Mellor, David H. Munn, Gang Zhou · 2010 · Blood
  73. PD-1 ligands, negative regulators for activation of naïve, memory, and recently activated human CD4+ T cells
    Guifang Cai, Arnon Karni, Enedina Maria Lobato de Oliveira, Howard L. Weiner, David A. Hafler, Gordon James Freeman · 2004 · Cellular Immunology
  74. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
    Shuguang Tan, Catherine W-H Zhang, George F. Gao · 2016 · Signal Transduction and Targeted Therapy
  75. Immune checkpoint inhibitors: new strategies to checkmate cancer
    Ruairí Wilson, Thomas R. Jeffry Evans, Alasdair R. Fraser, Robert J. B. Nibbs · 2017 · Clinical & Experimental Immunology
  76. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies
    Gen‐Sheng Feng, Kaisa L. Hanley, Yan Liang, Xiaoxue Lin · 2020 · Hepatology
  77. The PD-1:PD-L1 axis in Inflammatory Arthritis
    Mary Canavan, Achilleas Floudas, Douglas James Veale, Ursula Fearon · 2021 · BMC Rheumatology
  78. Targeting hypoxia at the forefront of anticancer immune responses
    Noman, Muhammad Zaeem, Chouaib, Salem · 2014 · OncoImmunology
  79. Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications
    Seungbo Yoo, Sang‐Jun Ha · 2016 · Immune Network
  80. The balance of immune responses: costimulation verse coinhibition
    Sumit Kumar Subudhi, Maria‐Luisa Alegre, Yang‐Xin Fu · 2005 · Journal of Molecular Medicine
  81. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
    Libin Zhang, Yanhui Chen, Han Wang, Zheyuan Xu, Yang Wang, Sixing Li, Jun Liu, Yun Chen, Hongli Luo, Lijia Wu et al. · 2021 · Journal for ImmunoTherapy of Cancer
  82. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
    Mikayel Mkrtichyan, Namju Chong, Rasha Abu Eid, Anu Wallecha, Reshma Singh, John Rothman, Samir N. Khleif · 2013 · Journal for ImmunoTherapy of Cancer
  83. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
    Hongchuan Liu, Lijing Guo, Jing Zhang, Yuehua Zhou, Jinwei Zhou, Jian Yao, Hai Wu, Sheng Yao, Bo Chen, Yan Chai et al. · 2019 · mAbs
  84. Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
    Robert A. Belderbos, Joachim G.J.V. Aerts, Heleen H. Vroman · 2019 · Molecular Therapy — Oncolytics
  85. Prostate Cancer Immunotherapy
    Kenneth F. May, James L. Gulley, Charles G. Drake, Glenn Dranoff, Philip W. Kantoff · 2011 · Clinical Cancer Research
  86. miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy
    Meng Zhang, Yanmei Shi, Yujuan Zhang, Yifan Wang, Faizah Alotaibi, Li Qiu, Hongmei Wang, Shanshan Peng, Yanling Liu, Qing Li et al. · 2020 · Cancer Immunology Immunotherapy
  87. Tumor-Induced Immune Suppression ofIn vivoEffector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor β
    Shuang Wei, Andrew B. Shreiner, Nobuhiro Takeshita, Lieping Chen, Weiping Zou, Alfred E. Chang · 2008 · Cancer Research
  88. Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
    Michael Melzer, Arturo Lopez-Martinez, Jennifer Altomonte · 2017 · Biomedicines
  89. Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
    Misako Matsumoto, Yohei Takeda, Megumi Tatematsu, Tsukasa Seya · 2017 · Frontiers in Immunology
  90. Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD ‐1high Breg cells
    Yu Mao, Yimin Wang, Lixin Dong, Qiang Zhang, Chao Wang, Yanqiu Zhang, Xin Li, Zhanzhao Fu · 2019 · Cancer Science
  91. Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
    Panagiotis Ntellas, Leonidas Mavroeidis, Stefania Gκoura, Ioanna Gazouli, Anna-Lea Amylidi, Alexandra Papadaki, George Zarkavelis, Davide Mauri, Georgia Karpathiou, Evangelos Kolettas et al. · 2020 · Cancers
  92. Role of regulation of PD-1 and PD-L1 expression in sepsis
    Teng Zhang, Li Yu-Jing, Tao Ma · 2023 · Frontiers in Immunology
  93. Tumor immune escape: extracellular vesicles roles and therapeutics application
    Mahdi Ahmadi, Reza Abbasi, Jafar Rezaie · 2024 · Cell Communication and Signaling
  94. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines
    Jens Rüter · 2009 · Frontiers in bioscience
  95. Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes
    Kristian Michael Hargadon, C. Colin Brinkman, Stacey L. Sheasley-O’Neill, Lisa A. Nichols, Timothy N. J. Bullock, Víctor H. Engelhard · 2006 · The Journal of Immunology
  96. Considerations for successful cancer immunotherapy in aged hosts
    Hurez, V, Padrón, Á S, Svatek, R S, Curiel, T J · 2016 · Clinical and Experimental Immunology
  97. Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma
    Elizabeth Ann L. Enninga, Shernan G. Holtan, Douglas J. Creedon, Roxana Stefania Dronca, Wendy Kay Nevala, Simona Ognjanovic, Svetomir N. Markovic · 2014 · Mayo Clinic Proceedings
  98. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
    Lana Elias Kandalaft, Cheryl Lai-Lai Chiang, Janos Laszlo Tanyi, Gregory T. Motz, Klara Balint, Rosemarie Mick, George Coukos · 2013 · Journal of Translational Medicine
  99. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer
    Vincent Lavoué, Aurélie Thedrez, Jean Lévêque, Fabrice Foucher, Sébastien Henno, Vincent Jauffret, Marc‐Antoine Belaud‐Rotureau, Véronique Catros, Florian Cabillic · 2013 · Journal of Translational Medicine
  100. Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer
    Neelam Z. Mukherjee, Niannian Ji, Vincent J. Hurez, Tyler Jay Curiel, Maureen O. Montgomery, Andrew J. Braun, Marlo M. Nicolas, Marcela Aguilera, Dharam Kaushik, Qianqian Liu et al. · 2018 · Oncotarget